Brandon Law
Director – Clinical Development Bristol Myers Squibb
At Bristol Myers Squibb, I direct Early Clinical Development for autoimmune cell therapy, helping drive new treatments with the goal of achieving immune reset.
I’m also an actively practicing Rheumatologist at Massachusetts General Hospital, where I specialize in the study and treatment of autoimmune diseases, including Sjögren’s Disease.
Seminars
Wednesday 25th March 2026
Tackling Immune Resetting in Multiple Sclerosis Through Translating CNS-Targeted B-Cell Depletion into Long-Term Remission
3:30 pm
- Understanding the therapeutic promise of CAR-T through its ability to cross the blood-brain barrier to achieve immune reset by eliminating the CNS-resident B-cells driving progressive MS pathology
- Leveraging the immune-resetting potential through early intervention to prevent the accumulation of permanent disability rather than treating symptoms of a late-stage progressive disease
- Establishing the clinical trial endpoints and regulatory frameworks necessary to prove the durable, long-term benefit and commercial viability of single-dose, curative therapies in a diverse patient population
Wednesday 25th March 2026
Panel Discussion: Defining Patient Populations for B-Cell Depletion Therapies & Establishing a ‘Window of Opportunity’ for Treatment
4:30 pm
- Determining the optimal time to deploy B-cell depletion, focusing on using ‘immune reset’ therapies early in the course of the disease development
- Comparing the efficacy of standard peripheral B-cell depletion against next-generation therapies designed to achieve a complete, deep-depletion
- Defining new clinical endpoints and securing regulatory approval for a curative-intent treatment that aims to halt disease progression early across a broad, heterogeneous autoimmune patient population
